Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
In Phase 2 trials at the 12 mg dose, participants lost an average of 24.2% of their body weight over 48 weeks
State Medicaid programs will also have access to these medications at these prices. CNBC reported on November 6, 2025, that Medicare will start covering obesity drugs for some patients for the first time starting mid-2026, a long-awaited move that could broaden the market for the medicines and spur more private insurers to cover them. A senior administration official explained the rationale to CNBC: We are constraining the access for patients that will benefit clinically from it, weve worked very hard to strike a balance between broad access that just makes sure to capture patients that will benefit clinically. Documentation of these qualifying conditions will be essential for coverage approval
Your stomach is unable to empty its contents
By week 12, the mean blood pressure decreased from baseline in the LY group compared to the placebo group
As of 2026, the most frequently cited conditions in these legal actions include gastroparesis, cholecystitis (gallbladder inflammation), gallstones, and intestinal obstruction
US$ 25.30
US$ 25.09
US$ 26.61
US$ 25.01
US$ 29.57
US$ 28.89
US$ 20.48
US$ 24.40
US$ 20.79
US$ 26.40
US$ 25.70
US$ 22.87
